Bavarian Nordic pressed as gauge company's product launch goes slow

Bavarian Nordic (CPH: BAVA) was pressed as Dendreon Corporation’s stock bombed some 65% percent this week. The Seattle, US based Dendreon announced much weaker than expected sales of its therapeutic cancer vaccine Provenge for the treatment of symptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Bavarian Nordic’s is developing its own therapeutic cancer vaccine candidate Prostvac, which is moving into late-stage clinical development for recurring advanced prostate cancer. Bavarian Nordic's stock suffered a 15% drop of its own.